O'Dell Group’s Sarepta Therapeutics SRPT Stock Holding History

O'Dell Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20	Closed	-$1.93K	–	420
2023 Q4	$1.93K	Buy	+20	New	+$1.92K	﹤0.01%	451

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

O'Dell Group's SRPT Position: Q1 2024 in Review

O'Dell Group sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 20 shares — an estimated $1.93K sold.

O'Dell Group first reported a position in SRPT in Q4 2023 and held it in 1 quarter. The position peaked at $1.93K in Q4 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

O'Dell Group reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
O'Dell Group sold 20 Sarepta Therapeutics shares in Q1 2024, an estimated $1.93K.
O'Dell Group first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 1 quarter.
O'Dell Group's Sarepta Therapeutics position peaked at $1.93K in Q4 2023.
414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on O'Dell Group's 13F filing for Q1 2024, filed 7 May 2024.